Home > Focus Areas > COPD Connect > Post
  • Saved

1yr
Optimizing COPD Treatment: Prioritizing LAMA/LABA Therapy for Stable Patients

The 2025 GOLD report reinforces the importance of LAMAs (Long-Acting Muscarinic Antagonists) and LABAs (Long-Acting Beta-Agonists) as key components of maintenance therapy for most COPD patients, particularly for non-high-risk patients with low eosinophil counts (<300 cells/µL). These recommendations emphasize initiating LAMA/LABA combinations early in treatment to prevent disease progression and reduce exacerbation risks, while de-escalating from ICS-containing regimens when appropriate.

For stable COPD patients with infrequent exacerbations, focusing on LAMA/LABA therapy offers an effective approach to long-term disease management, aligning with evidence that supports minimizing ICS use in low-eosinophil populations. This shift prioritizes maintenance therapies tailored to patient profiles, ensuring better adherence and reduced side effects.

Preventive strategies, such as vaccination against respiratory infections, including RSV, play a critical role in managing stable COPD patients, supporting a comprehensive approach to improving outcomes and slowing disease progression.

How are you incorporating LAMA/LABA therapies into your COPD management strategies? What approaches have you found most effective for optimizing maintenance therapy in stable patients?

  • 1yr
    I regularly use combo bronchodilators for patients with copd and persistent dyspnea. They are particularly effective for patients without a history of exacerbations. I do regularly evaluate lab work to rule out th2-mediated inflammation. If there is evidence of this I tend to add in an ics inhaler. I think consistency is key for these patients. If they derive benefit and understand the nature of chronic lung disease they tend to be compliant.
  • 1yr
    I utilize LAMA/LABA therapies regularly in my patients with COPD who are not having frequent exacerbations or have significant eosinophilia. I will typically use them in both GOLD A and B patients as there is little drawback to their use in these situations and they have the ability to significantly improve symptoms. I find that maximizing bronchodilation with LAMA/LABA therapies in combination can help to improve patient symptoms and reduce risk of exacerbation and improve their quality of life in general.
  • 1yr
    doing it for last 4-5 years, with pretty good response ( and less steroid related complications)
  • 1yr
    doing it for last 4-5 years, with pretty good response ( and less steroid related complications)
  • 1yr
    doing it for last 4-5 years, with pretty good response ( and less steroid related complications)
  • 1yr
    I also typically initiate therapy in newly diagnosed patients and usually follow their clinical response in follow up visits… how many times they are using their rescue inhalers is usually a pretty reliable way of following the efficacy of therapy as well as hopefully a reduction in hospital visits
  • 1yr
    I typically initiate LABS/LAMA on patients newly diagnosed with COPD. Prefer to minimize steroids unless inflammation present (elevated eosinophils). My patients generally tolerate treatment well. Insurance coverage can be a hassle at times. This can impact patients wanting to continue inhalers if their symptoms are improving. Generally recommend indefinite use but would repeat PFTs periodically and monitor for exacerbations.
  • 1yr
    I would agree with this and do this in my practice.
  • 1yr
    I would agree with this and do this in my practice.
  • 1yr
    I would agree with this.
  • 1yr
    Typically LABA/LAMA is first line at this point; unless mild obstruction/mild symptoms. Significant bronchodilator response must consider risk of LABA without ICS however. Escalate therapy based on response.
  • 1yr
    Now we have clinical evidence based guideline such as GOLD to provide concise recommendation for optimal maintenance treatment of stable COPD patients, LABA/LAMA is almost my first line therapy with fewer side effects. Additional therapy can be further escalated as clinical and/or biomarker are appropriate. We are entering an era of COPD treatment.

Show More Comments